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http://www.actaneurocomms.org/content/2/1/53RESEARCH Open AccessComplement activation in multiple sclerosis
plaques: an immunohistochemical analysis
Gillian Ingram1†, Sam Loveless2†, Owain W Howell3, Svetlana Hakobyan2, Bethan Dancey2, Claire L Harris2,
Neil P Robertson1, James W Neal2 and B Paul Morgan2*Abstract
Introduction: Inflammation and complement activation are firmly implicated in the pathology of multiple sclerosis;
however, the extent and nature of their involvement in specific pathological processes such as axonal damage,
myelin loss and disease progression remains uncertain. This study aims to bring clarity to these questions.
Results: We describe a detailed immunohistochemical study to localise a strategically selected set of complement
proteins, activation products and regulators in brain and spinal cord tissue of 17 patients with progressive multiple
sclerosis and 16 control donors, including 9 with central nervous system disease. Active, chronic active and chronic
inactive multiple sclerosis plaques (35 in total) and non-plaque areas were examined.
Multiple sclerosis plaques were consistently positive for complement proteins (C3, factor B, C1q), activation products
(C3b, iC3b, C4d, terminal complement complex) and regulators (factor H, C1-inhibitor, clusterin), suggesting continuing
local complement synthesis, activation and regulation despite the absence of other evidence of ongoing inflammation.
Complement staining was most apparent in plaque and peri-plaque but also present in normal appearing white matter
and cortical areas to a greater extent than in control tissue. C1q staining was present in all plaques suggesting a
dominant role for the classical pathway. Cellular staining for complement components was largely restricted to reactive
astrocytes, often adjacent to clusters of microglia in close apposition to complement opsonised myelin and damaged
axons.
Conclusions: The findings demonstrate the ubiquity of complement involvement in multiple sclerosis, suggest a
pathogenic role for complement contributing to cell, axon and myelin damage and make the case for targeting
complement for multiple sclerosis monitoring and therapy.
Keywords: Multiple sclerosis, Demyelination, Complement, Immunology, Histology, ImmunohistochemistryIntroduction
Multiple sclerosis (MS) is a chronic neuroinflammatory
disease characterised by well demarcated white matter
(WM) plaques of demyelination with varying degrees of
axonal loss [1]. It is widely accepted that the disease
process is initiated by adaptive immunity through infil-
tration of activated T cells into the CNS with associated
up-regulation of proinflammatory mediators. However,
the lack of lymphocyte recruitment after the initial re-
lapsing phase of disease indicates that other factors drive
pathology in late stage disease and there is increasing* Correspondence: morganbp@cardiff.ac.uk
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.evidence implicating plasma cells and innate immunity
in progressive disease [2].
Complement plays a central role in the innate immune
system, providing an important defence against infection
and immune complex disease. The system consists of
approximately 30 circulating and membrane expressed
proteins and is predominantly activated via the classical,
alternative pathway or lectin pathways. These converge
on a common effector pathway with formation of mem-
brane attack complex (MAC) (which disrupts and forms
pores in the phospholipid bilayer of a target cell), opso-
nins (molecules that enhance the ability of macrophages
and neutrophils with complement receptors to phagocyt-
ose material - C3b, iC3b, C4b etc.) and anaphylatoxins
(peptides that induce local and systemic inflammatory
responses, increasing the permeability of blood vesselsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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properties - C3a, C4a and C5a). Inappropriate activation
of complement is normally prevented by complement
inhibitors. A role for the complement system in MS has
been established and is reviewed in Ingram 2010 [3]. Evi-
dence implicating complement in MS came from studies
measuring complement proteins in MS CNS tissue,
plasma and CSF [4-6]. Numerous immunohistochemistry
studies described the presence of complement proteins in
and around areas of pathology in MS WM; however, ana-
lyses were generally limited to one or a few complement
proteins and small numbers of cases [7-13]. Together, the
published studies do not build consensus on whether
complement protein immunoreactivity is a consistent fea-
ture in MS, which areas of the CNS demonstrate immu-
noreactivity, or which complement proteins and pathways
are involved. This is likely due to studies including tissue
from different stages of the disease, limited numbers of
patients examined and variability in quality of detection
reagents used. The cumulative evidence suggests that only
tissues from cases with established and progressive disease
demonstrate consistent complement staining [11]. In
addition very few studies have attempted to define
underpinning mechanisms of complement involvement in
MS and its contribution to the various components of
demyelination and axonal damage. A notable exception
was a study by Prineas who showed abundant C3d
deposition on myelin in areas of pathology and suggested
a direct role as an opsonin driving immune response to
myelin antigens [9].
The paucity of robust data and the lack of consensus
noted above provoked us to look again at complement
proteins in MS CNS tissue. We describe a systematic
immunohistochemical analysis of the presence and
localisation of key complement components, activation
products, regulators and receptors in tissue from well-
documented progressive MS. We find that the presence
of complement proteins and activation products in and
around areas of pathology is a consistent feature of pro-
gressive MS, although the extent varies between individ-
uals. We note in particular, universal C1q staining
indicative of classical pathway activation, and consistent
staining for complement activation products, including
in most cases the terminal complement complex (TCC),
indicating activation to completion. These data bring
clarity to a confused field, establish the significance of
complement in the pathology of progressive MS and
provide an evidence base for targeting complement in
diagnosis, monitoring and therapy of MS.
Materials and methods
Cases
Archival blocks comprising 10% formalin-fixed, paraffin-
embedded CNS tissue obtained at autopsy from 17clinically and neuropathologically validated MS cases
and 16 controls, including 9 controls with other CNS in-
flammatory and non-inflammatory diseases (labelled
neurological controls) were used in this study (patient
and control details in Table 1). Tissue was obtained from
cerebral cortex from all cases and controls, and from
spinal cord from 11 cases and 8 controls. MS and non-
neurological control tissue was provided by the UK MS
Tissue Bank, Imperial College London. Neuroinflamma-
tory disease control tissue was from the Thomas Willis
Brain Bank, Oxford University and Brains for Dementia
Research, Brain Bank, IOP, King’s College London. In
each case clinical and demographic details and interval
between death and tissue collection were provided.
Ethical approval was gained from the South East Wales
Research Ethics Committee (10/WSE02/4).
Histological staining and lesion characterisation
Paraffin wax tissue sections 4 microns in thickness were
cut and stained with Luxol fast blue (LFB) to assess
presence of myelin and identify areas of demyelinated
plaque, peri-plaque and normal-appearing WM. This
allowed identification of lymphocytes, plasma cells and
foamy macrophages containing myelin degradation
products (also positive with anti-MOG staining). Areas
selected as normal-appearing WM were at least 1 cm
away from the edge of the demyelinating plaque. Cor-
tical grey matter (GM) was identified adjacent to and
sometimes continuous with the peri-plaque; the GM
areas showed neither meningeal inflammation nor peri-
vascular inflammatory cells.
Anti-HLA-DR antibody was used to identify microglia
and anti-MOG antibody to detect myelin. MS lesions
were classified as either classical active (profound in-
flammation with microglia and macrophages containing
myelin degradation products) or slowly expanding (cen-
tral profound axonal loss with loss of macrophages, with
a rim of activated microglia and moderate inflammation)
[14]. Slowly expanding lesions were further subdivided
into either chronic active (residual plaque centre inflam-
mation and profound microglial inflammation at the
plaque border) or chronic inactive (immunologically si-
lent lesion centre with a well demarcated lesion border
showing only mild inflammation) (examples shown in
Figure 1) [14]. Spinal cord sections were also analysed
for plaque subtype according to this classification. To
ensure accuracy of lesion classification, all sections were
assessed by three independent trained observers (JWN;
OWH; GI); inter-observer concordance was 100%.
Immunohistochemistry
Paraffin wax sections were de-paraffinated using xylol
and rehydrated in serial aqueous dilutions of ethanol
(100%, 96%, 70%, 0%). For antigen retrieval, sections
Table 1 Patient clinical characteristics details
Case number Disease status Age at death Sex Death to TPT DD Cause of death
MS055 SPMS 47 F 15 32 Pneumonia
MS058 SPMS 51 F 15 21 MS
MS061 PRMS 56 F 6 >15 Adenocarcinoma
MS064 SPMS 66 M 56 28 Pneumonia
MS128 SPMS 78 F 22 50 Pneumonia
MS179 SPMS 70 F 20 25 Pneumonia
MS306 SPMS 78 M 17 42 Clostridium difficile diarrhoea
MS307 SPMS 55 M 19 20 MS
MS312 SPMS 68 F 24 23 Urinary sepsis
MS372 SPMS 82 F 7 46 Pneumonia
MS383 PPMS 42 M 17 8 Pneumonia
MS24 PPMS 71 F 96 22 Pneumonia
MS160 SPMS 44 F 18 16 Pneumonia
MS225 SPMS 79 F 23 32 MS, Diabetes mellitus, deep vein thrombosis
MS230 SPMS 42 F 31 19 MS
MS234 SPMS 39 F 15 15 Pulmonary embolism/Pneumonia
MS377 SPMS 50 F 22 23 Pneumonia
C21 C 91 F 127 N/A Pneumonia
C29 C 71 M 33 N/A Abdominal haemorrhage
C23 NC 93 F 51 N/A Alzheimer’s disease
C36 C 68 M 30 N/A Cryptogenic fibrosing alveolitis
C37 C 84 M 5 N/A Pneumonia, bladder cancer
C38 C 85 M 27 N/A Ischaemic heart disease
C39 C 82 M 21 N/A Myelodysplastic syndrome
C40 NC 86 F 29 N/A Acute cortical ischemic infarction
C41 C 54 M 20 N/A Lung cancer
NP7407-2 NC 93 F 24 N/A Acute cortical ischemic infarction
1228/91-b NC 88 F 24 N/A Acute cortical ischemic infarction
A140_07 NC 81 F 17 N/A Alzheimer’s disease
A173_08 NC 85 F 30 N/A Alzheimer’s disease
A192_2 NC 96 F 19 N/A Alzheimer’s disease
B5046-15 NC 42 M 72 N/A Herpes simplex encephalitis
B5125-9 NC 54 M 96 N/A Herpes simplex encephalitis
SPMS: secondary progressive MS; PRMS: progressive relapsing MS; PPMS: primary progressive MS; NC: Neurological Control; C: non-neurological control with no
known history of neurological disease; F: female; M: male; TPT: Tissue preservation time in hours; DD: disease duration.
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mins at 100°C) or immersed in protein kinase 20 μg/ml
(20 mins at 37°C; for primary antibody B7 only). Prior to
staining, sections were blocked in 10% normal goat
serum. To ensure optimal consistency, staining was per-
formed using an autostainer (DAKO EnVision™ + System).
Endogenous peroxidase was blocked by 10 mins incuba-
tion in 3% H2O2. Primary antibodies, including antigen
target, clone, concentration, dilution and source, are listed
in Additional file 1: Table S1. Appropriate secondaryantibodies were from Dako and DAB chromogen was
used for visualisation.
Double labelling was performed with two peroxidase
steps according to the manufacturer’s recommended
protocols (www.vectorlabs.com, A guide to multiple
antigen labelling); blocked sections were incubated for
1 hour with the first primary antibody followed by 30
mins with the appropriate peroxidase-labelled secondary
antibody and then stained using Vector SG peroxidase
substrate kit (Vector Laboratories, www.vectorlabs.com).
Figure 1 Plaque morphology in MS cases. Paraffin wax sections stained with LFB (A1, B1 and C1) and anti-HLA DR (A2, B2 and C2) showing
an active (A1-A2; case MS160_S3), chronic active (B1-B2; case MS225_S13) and chronic inactive plaque (C1-C2; case MS61_B). The active plaque
shows profound inflammation with anti-HLA-DR immunopositive microglia (A2 and inset) and foamy macrophages containing myelin degradation
products demonstrated using LFB (inset in A1). The chronic active plaque shows little inflammation in the centre of the plaque (insets in B1 and B2)
but abundant anti-HLA-DR immunopositive microglial at the plaque border (B2). The chronic inactive plaque shows an immunologically silent lesion
centre (inset in C1 and C2) and a well demarcated lesion border showing only mild inflammation (C2 and inset) Scale bars are shown in B2 and are
applicable for all plates and inserts.
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10% normal goat serum, incubated for 1 hour with the
second primary antibody and for 30 mins with the
peroxidase-labelled secondary antibody which was visua-
lised with DAB chromogen. In this system the peroxid-
ase substrate yields a grey stain and the DAB label a
brown stain, enabling the two primary antibodies to be
visualised on the same slide in different colours. Thesections were dehydrated prior to permanent mounting
in DPX.
For immunofluorescence, sections were stained se-
quentially for complement and cell specific markers at
room temperature, according to published protocols
[15]. When two monoclonal antibodies of different IgG
isotypes were tested (HLA-DR (IgG1) and complement
activation product iC3b (IgG2a), for example), then
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jugate (Stratech Scientific, Newmarket, UK), and biotin-
linked goat anti-mouse IgG2a (Abcam, Cambridge, UK)
and streptavidin- Alexa 594 (Life Technologies, Paisley,
UK), were applied sequentially. Negative controls were
run in parallel, and involved omission of one or both pri-
mary antibodies and/or inclusion of an irrelevant isotype
control antibody. All such controls were devoid of stain-
ing. Following incubations with the secondary antibodies,
all sections were counterstained with 4′,6-Diamidino-2-
phenylindole dihydrochloride (DAPI; Sigma), quenched in
0.1% w/vol Sudan black B (VWR International), rinsed in
deionised water and coverslipped with Vectashield aque-
ous mountant (Vector Labs, Peterborough, UK).
Sections were analysed on a Zeiss Axio Imager 2
under epifluorescence and images captured using a Zeiss
AxioCam MRm camera or by confocal laser scanning
microscopy with Zeiss LSM-710 and inverted Axio Ob-
server microscope with oil-immersion 40X and 63X ob-
jectives. All images were analyzed off-line using ImageJ
(http://rsb.info.nih.gov/ij/) and prepared in Photoshop
CS2 (Adobe Systems, Uxbridge, UK) for publication.
Positive control tissue sections for testing the anti-
complement antibodies comprised arrayed fixed tissue
sections [16] from renal biopsies taken from glomerulo-
nephritis patients and myocardium from a patient with
myocarditis due to adenovirus; all antibodies positively
labelled these sections using the described protocols
(Additional file 2: Figure S1).
Quantitative analysis
All stained sections were digitally scanned at x40 magni-
fication of the objective lens (0.037 mm2/field). In each
section, areas representative of plaque (P), peri-plaque
(PP), WM and GM were identified and five different
fields from each area were selected manually for further
analysis. For quantification, the selected fields were over-
laid with a grid and positively labelled cells within the
grid for each of the individual antibodies were manually
counted. Values were expressed as the number of posi-
tively labelled cells per mm2. In order to verify data,
inter-rater agreement was assessed between two inde-
pendent trained observers (GI; SL) over 30 scanned
fields from different sections, patients and primary anti-
bodies; inter-observer correlation coefficient was 0.99.
Non-cellular interstitial staining and myelin staining was
classified as either negative (−), weakly positive (+),
moderately positive (++) or strongly positive (+++)
based on criteria established in house [17].
Statistical analysis
Data analysis was performed using Statistical package for
Social Sciences version 20 (SPSS, Chicago, USA). Data
were not normally distributed and therefore were analysedusing non-parametric tests. MS patients were compared
to normal and neurological control groups using the
Kruskal-Wallis Test for independent values. Where posi-
tive, subgroups were analysed using the Mann–Whitney
U test. Differences between MS disease subgroups (P, PP,
WM, GM) were analysed using Freidman’s ANOVA and
where positive, post-hoc procedures were performed using
the Wilcoxon Signed Ranks Test. Differences between ac-
tive, chronic active and chronic inactive plaques were ana-
lysed using the Kruskal-Wallis Test for independent
values. Where positive, subgroups were analysed using the
Mann–Whitney U test. For most tests a P value of <0.05
was considered significant. For subgroup analysis to com-
pensate for the inflation of type I errors due to multiple
testing, a p value of <0.025 was taken as significant (0.05
divided by the number of tests).
Results
Characteristics of MS lesions studied
All cases examined were from patients with progressive
MS, most with long-standing disease (mean disease dur-
ation 26 +/− 12 yrs, mean age at death 59 +/− 15 yrs)
(Table 1). Both control groups had higher mean age at
death (non-neurological controls 76 +/− 13 yrs, p = 0.021;
neurological controls 80 +/− 19 yrs, p = 0.003). There were
no significant differences between the time to tissue pres-
ervation (TTP) in each group (MS 24.88 +/− 21.36 hrs;
non-neurological controls 37.57 +/− 40.48 hrs, p = 0.317;
neurological controls 40.22 +/− 27.35 hrs, p = 0.190). MS
lesions were classified depending on lesion activity. Of the
35 plaques examined, 8 were classified as active and 27 as
slowly expanding, 9 of the chronic active and 18 of the
chronic inactive type (Figure 1). An additional seven MS
sections examined comprised only WM and GM with no
plaque. MS sections were almost devoid of lymphocytes
or plasma cells with only a few T or B cells identified
within the blood vessel wall and perivascular space and an
occasional T cell observed within the plaques of active le-
sions (Additional file 2: Figure S1). CNPase positive oligo-
dendrocytes were universally absent from all plaques
examined. In MS WM and GM, astrocyte cell counts were
not significantly different from non-neurological or neuro-
logical controls (Figures 2 and 3); however microglial cell
counts were significantly higher in MS WM than non-
neurological control WM, but higher still in the WM and
GM of the neurological control group (this being the area
of pathology in this group).
Complement immunolabelling is ubiquitous in MS lesions
Complement protein immunolabelling was observed in
all sections from MS cases to some degree; in contrast,
immunolabelling was completely absent in two of seven
non-neurological controls and minimal, in the other
five. Staining in non-neurological controls was largely
Figure 2 (See legend on next page.)
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Figure 2 Quantitation of cell immunolabelling. Quantitative cellular immunolabelling in brain and spinal cord tissue from multiple sclerosis
(MS; 17 cases with 690 areas examined from 42 sections), non-neurological controls (Controls; 7 cases with 140 areas examined from 14 sections)
and neurological controls (NC; 9 cases with 110 areas examined from 11 sections). Groups show total mean values from all areas examined
+/_ standard error. Significant results are shown by p value examining differences between the MS group and controls or neurological controls;
differences between the two control groups were not included for reasons of clarity.
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except for antibodies against C3b, clusterin, fH-Tyr402
and C1inhibitor (C1inh) which significantly stained cells
in some controls (Figure 2). One of nine neurological con-
trols (an Alzheimer’s disease case) showed no complement
staining, but for the other neurological controls, staining
for most complement proteins was seen in a similar num-
ber of cases to that in MS; the exception was C1q staining
which was significantly higher in MS tissue (Figure 2).
Paraffin wax sections from kidney tissue with glomerulo-
nephritis and myocardium with viral myocarditis showed
immunolabelling in relevant areas for all antibodies used
(Additional file 2: Figure S1). Sections stained with isotope
control antibodies (IgG1 or IgG2) were consistently
negative in both MS cases and controls (Additional file 2:
Figure S1).
Complement immunolabelling in MS is predominantly
cell-associated
The majority of observed complement immunolabelling
in MS cases was cell-associated, either surface or within
the cell (not distinguishable in immunohistochemistry),
while cell immunolabelling in non-neurological controls
was weaker and predominantly nuclear (Additional file 2:
Figure S1). Cell immunolabelling in the neurological con-
trol group was marked, especially in areas of inflammation
and obvious disease pathology, for example, in and around
Alzheimer’s plaques (Additional file 2: Figure S1).
Cell complement immunolabelling within the plaque
and peri-plaque areas in MS sections was consistently
associated with cells morphologically resembling astro-
cytes for all complement proteins tested except the ana-
phylatoxin receptors C3aR and C5aR (Figures 4, 5 and
Additional file 3: Figure S2). Double immunolabelling
confirmed this observation; C1q and C3b co-localized
with GFAP + reactive astrocytes within the plaque and
peri-plaque (C3b in this manuscript refers to immunola-
belling with the C3b/iC3b-specific monoclonal antibody
C3/30) (Figures 4 and 5). C1q and C3b stained reactive
astrocytes were often in close proximity to clusters of
HLA-positive microglia with activated morphology and
macrophages containing complement-stained debris, seen
especially in active plaque centres (Figures 4 and 5). C1q
also co-localized with HLA + activated microglia, contrib-
uting to the increased cell-associated C1q immunolabelling
in the peri-plaque (Figures 3 and 4); these cells were also
positive for anaphylatoxin receptors C3aR and C5aR(Additional file 3: Figure S2). GFAP positive astrocytes
within the GM did not stain for complement; indeed, com-
plement immunolabelling of all complement antibodies
within the GM in MS and controls was mainly limited to
neurones (Additional file 4: Figure S3).
The number of cells immunolabelling for each comple-
ment protein was counted in all fields and compared, MS
with controls, and within the MS sample, plaque, peri-
plaque, WM and GM (Figures 2 and 3). Cellular immuno-
labelling of all complement antibodies in the neurological
control group was restricted to cells morphologically re-
sembling microglia within WM and neurones within GM.
No complement component immunolabelling was ob-
served on astrocytes in either normal or neurological con-
trol groups. This finding was confirmed with double
labelling experiments (Additional file 2: Figure S1).
Complement activation markers are characteristic of MS
Cellular and non-cellular immunolabelling for the clas-
sical pathway protein C1q was strongly positive in both
MS and neurological control groups; 100% of MS sec-
tions were stained for C1q compared to 77.8% of neuro-
logical control sections, while 10% (p < 0.001) of normal
control sections showed weak C1q staining (Additional
file 5: Figure S4). There were significantly more posi-
tively stained cells in MS sections compared to both
non-neurological and neurological controls (p < 0.001;
Figure 2). In MS sections, C1q immunolabelling was
found on cells morphologically resembling both astro-
cytes and microglia, most abundantly in the plaque and
peri-plaque areas but also in WM; in GM, C1q immuno-
labelling of neurones was seen (Figures 3 and 4).
The majority of MS sections were positive for the clas-
sical pathway activation fragment C4d (Additional file 5:
Figure S4); despite some cellular immunolabelling of C4d
in control sections, cell immunolabelling for C4d in MS
sections was markedly higher than in non-neurological
controls (p < 0.001, Figure 2), and was most abundant in
peri-plaque and plaque and minimal in WM (Figure 3). In
GM, some cell-associated (predominantly neuronal) C4d
immunolabelling, was present in all groups (Additional
file 4: Figure S3).
Alternative pathway activation fragment Bb (Bb) was
positive in 59.5% of MS sections compared to 7.1% (p <
0.001) of non-neurological controls and 54.5% of neuro-
logical controls (Additional file 5: Figure S4), indicating
ongoing activation of the alternative pathway in MS.
Figure 3 (See legend on next page.)
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Figure 3 Quantitative immunolabelling of cells from different tissue areas. Quantitative cellular immunolabelling in different tissue areas
from sections of brain and spinal cord tissue from multiple sclerosis (MS; 42 sections from 17 cases with 175 areas examined within the plaque
(P), 175 within the peri-plaque (PP), 145 within the white matter (WM) and 195 within the grey matter (GM)), non-neurological controls (C; 14
sections from 7 cases with 70 areas examined from both WM and GM) and neurological controls (NC; 11 sections from 9 cases with 55 areas
examined from both WM and GM). Groups show mean values +/_ standard error. Significant results are shown by p value examining differences
between the MS group and controls or neurological controls for both WM and GM; differences between the control groups were not included
for reasons of clarity. Within the MS group, differences were analysed between P and PP/PP and WM.
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trocytes, was most abundant within the peri-plaque and
plaque (p < 0.001; Figure 3), although Bb-immunostained
cells were present at increased levels in MS compared to
non-neurological controls in both WM and GM (p <
0.001; Figure 3), suggesting that alternative pathway acti-
vation occurred throughout the brain in MS, not just
within the plaque core.
Cell immunolabelling for C3b/iC3b was detected in al-
most all MS sections, but was also present in neuro-
logical controls and weakly in some non-neurological
controls (90.5% MS, 50% non-neurological controls (p <
0.001), 81.8% neurological controls; Additional file 5:
Figure S4); numbers of positively stained cells/mm2 in
MS sections were significantly higher compared to non-
neurological controls (p < 0.001; Figure 2); staining was
strongest in plaque and peri-plaque (Figure 3). These
findings were confirmed in three MS cases (MS 55, MS
61 and MS 64) using another mAb specific for iC3b
(A209, data not shown). Quantified cellular immunola-
belling of these two C3b/iC3b mAbs (C3/30 and A209)
showed an intraclass correlation coefficient of 0.85 (95%
CI 0.76-0.91, p < 0.001).
Terminal pathway activation assessed using a TCC-
specific mAb was positive in 71.4% of MS sections com-
pared with 7.1% of non-neurological controls (p < 0.001)
and 54% of neurological controls (Additional file 5:
Figure S4), with significantly more positively stained cells
in MS cases compared to non-neurological controls (p <
0.001, Figure 2). Immunolabelling for TCC was strongest
in the plaque and peri-plaque but was also present in
WM and GM where TCC immunolabelled cells (in MS
groups morphologically resembling astrocytes in the
WM (Additional file 4: Figure S3) and neurones in the
GM) were more frequent than in non-neurological con-
trols (p < 0.001 for both, Figure 3). Of note, all MS sec-
tions that contained TCC immunopositive cells also
showed comparable positive immunolabelling for C3b;
however, some sections positive for C3b showed weak or
absent TCC staining.
Cell expression of complement regulators and receptors
is altered in MS
To inform speculation regarding consequences of local
complement activation on CNS cells in MS, sectionswere stained with mAb specific for the key plasma-
derived complement regulators C1inh, factor H (fH) and
clusterin, and the anaphylatoxin receptors C3aR and
C5aR. This selection was pragmatic and dictated by
availability of mAb (in house or commercial) that were
suitable for use in formalin fixed tissue. Expression of
both classical pathway regulator C1inh and terminal
pathway regulator clusterin was found in most MS sec-
tions, strongest in astrocytes in the plaque and peri-
plaque area (Figure 3 and Additional file 4: Figure S3
and Additional file 5: Figure S4). Although cell expres-
sion of both C1inh and clusterin was stronger and more
frequent in MS compared to non-neurological controls
(Figure 2), there was background WM and GM immu-
nolabelling in both MS and control sections (Figure 3).
Expression of the alternative pathway regulator fH was
assessed using mAb specific for the Tyr402His poly-
morphic variants (described in [18]). Cellular immunola-
belling for either or both variants was seen in 13 of 17
MS cases with higher numbers of positively immuno-
labelled cells in the plaque and peri-plaque areas com-
pared to the WM (p < 0.001; Figure 3); cellular
immunolabelling for the two variants was positive in
each case. Eight of nine neurological controls showed
cell immunolabelling for Tyr402 and seven of these were
also His402 positive. Of the seven non-neurological con-
trols, five were Tyr402 positive and one was also positive
for His402 (Additional file 5: Figure S4). In MS sections,
26 of 42 showed immunolabelling for either or both var-
iants with high numbers of positively immunolabelled
cells in the plaque and peri-plaque areas compared to
the WM (p < 0.001; Figure 3); of the 26 positive sections,
6 stained only for Tyr402, 17 stained for both variants
and 3 stained only for His 402. In normal control sec-
tions, 9 of 14 sections showed immunolabelling, 8 of
these stained for Tyr402 only and one for both variants.
In neurological control sections, 6 of 11 sections showed
immunolabelling, 3 of these stained for Tyr402 only and
3 for both variants (Additional file 5: Figure S4).
Cellular immunolabelling of the anaphylatoxin recep-
tors C3aR and C5aR was restricted to microglia with
morphology compatible with activation. Immunolabel-
ling for C3aR was observed in 90% of MS sections and
40% of non-neurological controls (p = 0.004, s0al
Figure 4) whereas C5aR was observed in the majority of
Figure 4 Cell associated C1q complement staining. Paraffin wax sections A1, A2 and A3 (case MS160_S3, active case). A1 shows immunolabelling
with anti-C1q in plaque (P) and peri-plaque (PP) areas. A2 shows C1q immunopositive debris (brown) within foamy macrophages localized in the
centre of an active plaque. A3 shows C1q immunolabelled on myelin. B1 paraffin wax section double immunolabelled with anti-C1q (grey) and anti-
HLA-DR (brown) confirms C1q immunopositive debris located within HLA positive foamy macrophages cells; (case MS160_S3, active plaque). B2 and
B3 also show paraffin wax sections with immune double staining of anti-C1q and anti-HLA-DR (case MS230_s2, chronic active plaque). B2 shows HLA-
DR positive cells (brown) closely associated with C1q positive myelin (grey) within the white matter. B3 shows co-localisation of C1q on HLA-DR
positive microglia (arrows) in the peri-plaque. C1 (case MS372_22, chronic active plaque) and C2 (case MS230_S2, chronic active plaque, stained using
immunofluorescence (IFC)) show double labelling for C1q and GFAP, with colocalisation of C1q (grey) and GFAP (brown) in some but not all cells
(insert in C1 and arrow in C2 highlighting colocalisation). IFC in figure D1 (case MS377_S2, active plaque) and D2 (case MS160_S1, active plaque)
demonstrate anti-HLA-DR positive macrophages closely associated with C1q positive myelin (arrow). Inset in D2 shows C1q immunopositive debris
within an HLA-DR immunolabelled macrophage (arrow). E1 shows a myelin sheath at edge of an active plaque staining with anti-MOG (grey) and C1q
(brown) (case MS160_S3, arrow); in the same area E2 (IFC, case MS160_S3) shows a myelin sheath with positive anti-C1q immunolabelling. Figures F1
(MS160_S3/1; chronic active plaque) and F2 (MS336_1; active plaque), captured with confocal laser scanning microscopy, show disrupted myelin,
immuno-positive for C1q associated with anti-SMI-32 immunopositive non-phosphorylated axon profiles in chronic and active areas. Scale bars are
shown for each plate.
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nolabelled cells in MS cases and neurological controls
was almost 3-fold higher compared to non-neurological
controls (p < 0.001 for both C3aR and C5aR; Figure 2).
Cell immunolabelling for C3aR and C5aR in MS sec-
tions was highest in the peri-plaque compared to plaque
and WM (p < 0.001; Figure 3), with predominant co-localization with HLA positive microglia within the peri-
plaque areas (Additional file 3: Figure S2). C3aR immuno-
labelling was also observed on the cerebral vessel endothe-
lium and smooth muscle cells within the vessel wall in MS
tissue. C3aR and C5aR immunolabelling in WM and GM
was weak and not different in MS compared to non-
neurological control sections; in contrast in neurological
Figure 5 Cell associated C3b complement staining. Paraffin wax section of active peri-plaque regions (A, case MS377_S2; B, case MS383_21)
immunolabelled with anti-C3b showing cells with astrocytic morphology. Myelin degradation debris (arrows) within macrophages colabelled with
anti-C3b (brown) and MOG (grey) are shown within the centre of an active plaque (C, MS160_S3). Immunofluorescent staining: D1 (case MS
225_S13, chronic active plaque) and D2 (case 377_S2, active plaque) showing colabelling of C3b (red) and GFAP + astrocytes (green) in the peri-
plaque white matter. E1 (case MS225_S13, chronic active plaque; plaque (P) and peri-plaque (PP)), E2 and E3 (both case MS377_S2, active plaque)
show zones of HLA-DR macrophages/microglia and an adjacent area of predominantly astrocytic and axonal C3b immunolabelled structures. In
figure E3, note the close approximation of C3b positive axon (arrow) and HLA positive microglial cell. F shows an anti-C3b positive myelin strand
(brown, arrow) co-localised with MOG (grey) on an axon bundle within striatum (case MS160_S3, active plaque). Immunofluorescent staining (G),
showing anti-C3b immunopositive myelin (red) co-localised with an anti-SMI-32 (green), immunopositive non-phosphorylated axon at the edge
of a chronic active white matter lesion (case MS160_S3, active plaque). Scale bars are shown for each slide.
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microglial staining for C3aR and C5aR was consistently
found (Figure 3).
Complement immunolabelling of myelin is characteristic
of MS
Immunolabelling for one or more complement protein
was present on myelin, intact or with a fragmented or
disrupted appearance in 64.3% of MS sections compared
to 36.4% of neurological control sections and 28.6% of
non-neurological control sections (comparison of myelin
immunolabelling in MS versus non-neurological controls;
p = 0.035, Additional file 5: Figure S4). Complementimmunolabelling of myelin in MS was predominantly ob-
served in peri-plaque areas, with some immunolabelling
of fragmented myelin within plaques (Figures 4 and 5 and
Additional file 4: Figure S3). Of the MS sections, 14.3%
showed positive myelin immunolabelling for C1q, 7.1% for
Bb, 19% for C3b, but none were stained for TCC. Of the
regulators, 26.2% of MS sections showed positive myelin
immunolabelling for C1inh and 9.5% for clusterin; myelin
staining for fH variants was remarkable in that staining
for the less common fH-His402 variant was almost twice
as frequent as for the more common fH-Tyr402 variant
(31% versus 16.7% of sections and seven compared to five
out of 14 cases).
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except for low level C1inh staining in non-neurological
controls (one case) and staining for clusterin (one case)
and fH-His402 (two cases) in neurological controls;
however, because of the broad variability between sec-
tions for myelin immunolabelling, only fH-His402 was
significantly different from controls (Additional file 5:
Figure S4). In MS sections, myelin fragments immuno-
positive for complement proteins were frequently
present at the lesion edge, associated with both HLA-
positive microglia and SMI32-positive stressed/damaged
axons (Figures 4 and 5). These features were not ob-
served in control sections.
Complement immunolabelling marks active plaques
Significantly more immunolabelling of complement pro-
teins, activation products and regulators was observed in
the plaque and peri-plaque areas of active and chronic
active compared to inactive plaques (Additional file 6:
Figure S5). Overall there was little difference in comple-
ment immunolabelling observed between the active and
chronic active plaques except for two of the regulators
(fH-His 402 and clusterin) where immunolabelled cells
were observed more frequently in chronic active plaques
(Additional file 6: Figure S5).
Immunolabelling of C3aR was minimal in the active
plaque centres and peri-plaque areas, but seen much
more frequently in the inactive peri-plaque; where al-
though few microglia were observed, the majority of these
showed C3aR immunolabelling. C5aR immunolabelling
was observed equally in all plaque types (Additional file 6:
Figure S5).
All of the plaques in spinal cord sections examined
were inactive (making up ten of the 18 inactive plaques
examined). Immunolabelling for the majority of comple-
ment antibodies was similar to but significantly lower in
the spinal cord sections compared with brain sections,
except for the anaphylatoxin receptors in which immu-
nolabelled cells were observed more frequently in cord
(data not shown).
Discussion
There is on-going debate surrounding the contribution
of inflammation to the relentless axonal degeneration
seen in MS patients, clinically most apparent in progres-
sive disease; absence of immune cells and lack of efficacy
of anti-inflammatories has led some to postulate a com-
plex and as yet undefined neurodegenerative process to
explain the relentless brain atrophy [19]. We show that
complement proteins, activation products, regulators
and receptors are markers of CNS innate immune acti-
vation, present in active plaques but persisting even in
late stage disease when plaques become inactive, indicating
that synthesis, activation and regulation of complementare all on-going in plaque and peri-plaque areas of brain
and spinal cord in late-stage MS.
In chronic active and inactive plaques, complement
markers occurred in the absence of other inflammation
markers, including lymphocytes, plasma cells and foamy
macrophages; demonstrating that progression of inflam-
mation in MS CNS does not rely on infiltrating cells;
once initiated, inflammation can be driven by innate im-
mune mechanisms such as complement. These findings
support our previous studies showing systemic comple-
ment activation and regulation in MS throughout the
disease course [20]; in particular, increased serum fH
levels were specific to progressive disease and predicted
relapse [18], suggesting an active role in late stage
disease.
The profile of complement immunolabelled cells was
similar in patients with active and chronic active plaques
but markedly different in patients with other neuroin-
flammatory diseases - encephalitis, Alzheimer’s disease
and ischaemic infarction. In MS, complement staining
was predominantly associated with GFAP + astrocytes in
plaque and peri-plaque areas; in contrast, in neurological
controls, cellular complement staining associated with
microglia in WM and neurones in GM. In encephalitis
and ischaemic infarction cases, the time from patho-
logical insult to death was short in comparison to
Alzheimer’s disease and MS where complement expres-
sion and activation is maintained over years. In ischae-
mic infarction there is catastrophic blood brain barrier
(BBB) disruption, facilitating entry of complement; in
MS, Alzheimer’s disease and encephalitis where the de-
gree of BBB disruption is uncertain, local synthesis may
be an important contributor and it is known that glial
cells can produce all complement components needed
for terminal pathway activation [21].
Evidence implicating the classical pathway in MS
pathogenesis was described over thirty years ago. Im-
mune complexes were demonstrated in MS CSF and
brain with associated binding of C1q and classical path-
way activation [22]; in parallel, it was shown that oligo-
clonal immunoglobulins were present in CSF in most
MS patients [23], the result of intrathecal synthesis [24].
Even in the absence of antibody, the classical pathway
can be triggered by C1q directly binding damaged mye-
lin [25]. Here we confirm that C1q is a powerful disease
marker, present in all MS cases and minimal in controls.
C1q immunolocalized to reactive astrocytes, microglia
and myelin in peri-plaque and plaque areas; immunola-
belling does not distinguish between protein on and in
cells - it is entirely possible that astrocyte staining for
C1q and other complement proteins represents biosyn-
thesis, especially in inactive chronic lesions where BBB
breakdown is minimal. In contrast, astrocyte- and myelin-
associated C3- and C4-derived activation fragments and
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pathway activation and implies that at least some of the
C1q is on the astrocyte surface and activating. The alter-
native pathway marker Bb was positive in the majority of
MS cases, suggesting that amplification through this path-
way was a significant contributor.
Complement regulators assessed in this study showed
increased immunolabelling in plaque and peri-plaque
areas indicating the ongoing capacity for local comple-
ment inhibition throughout MS disease course. In light
of our published finding that the relative plasma levels
of the variants of regulator fH alter in progressive MS
[18], the Tyr402His polymorphic variants (minor allele
frequency 0.3) were separately measured; remarkably,
the relative staining of Tyr and His variants was mark-
edly different between MS cases and controls, suggesting
that there were qualitative differences in fH variant ex-
pression and/or deposition between cases and controls
with more frequent cell-associated fH, and in particular
the His402 variant, in MS. The functional consequences
and relevance to disease progression of this remain to be
ascertained; however, in age-related macular degener-
ation (AMD), differential binding of the fH-Tyr402His
variants in retina has been demonstrated and proposed
as the mechanism by which fH-His402 is risk for AMD
[26]. Of note, we previously demonstrated increased
plasma levels of fH and altered Tyr402His ratio in pro-
gressive MS with over-representation of His402 in het-
erozygous patients [18].
Our data demonstrate considerable heterogeneity of
complement immunolabelling in MS cases. Pathological
heterogeneity and heterogeneity of complement staining
in MS lesions was described by Lucchinetti and col-
leagues; they proposed four distinct patterns of MS le-
sions with only 50% of patients showing complement
immunolabelling, limited in their study to TCC immu-
nolabelling using the mAb B7, also used in our work
[10,27]. Others have contested this, using a wider range
of complement markers and reporting consistent com-
plement immunolabelling in all lesions and cases exam-
ined [11]. Our data agree in part with the findings of
Lucchineti in that 71% of sections were TCC+; however,
all were C1q +, most C3b/iC3b + and all TCC + sections
were strongly C3b/iC3b+. Together these data indicate
that complement staining is a ubiquitous feature of MS
lesions but the pattern of staining is variable. We suggest
that TCC is a reliable marker for complement activation
in MS; its near-complete absence in controls supports
its use in isolation as a marker. In our hands, very few
lesions were negative for TCC and C3b/iC3b and these
were C1q+, which may also be a useful marker despite
its presence in control tissues.
The predominant staining of reactive astrocytes for
complement activation products including iC3b andTCC has not previously been described in MS and was
disease-specific; complement activation marker staining
in neurological controls was extracellular and on micro-
glia/macrophages in the tissue. The data suggest that
this astrocyte-restricted pattern of complement staining
is specific to demyelinating disease. Complement-
mediated astrocytic impairment was recently described
in neuromyelitis optica [28]; our findings imply that this
may also be a feature of progressive MS. Complement-
stained astrocytes were often co-localised with clusters
of activated microglia, a finding that has previously been
reported in MS and linked to complement priming of
microglia contributing to CNS inflammation [29]. The
notion of astrocytes contributing to pathological process
in MS by enhancement of immune response and disrup-
tion of myelin has recently been raised in a number of
studies [30,31].
Immunolabelling of disrupted myelin in MS lesions,
previously cited as evidence of complement-mediated
pathology, was limited and variable in this study. Breij
et al. [11] described myelin staining for C3d but not
TCC in active lesions. Myelin staining for complement
proteins has been suggested to be a non-specific feature
[12]; however, using double immunolabelling we found
complement markers co-localized in areas of degenerat-
ing myelin and damaged axons in MS sections (Figures 4
and 5), implicating complement in axonal and myelin in-
jury in and around active and chronic plaques. Absence
of TCC may reflect efficient regulation of terminal path-
way activation at these sites or an inability of TCC/MAC
to intercalate into myelin. Clusters of activated microglia
were frequently found in close apposition to damaged
myelin, likely representing iC3b/CR3-mediated opsonic
clearance.
C3aR and C5aR were expressed on microglia in and
around the plaque, a finding previously reported in acute
plaques [32,33], but not in chronic active and inactive
slowly expanding lesions studied here; indeed, numbers
of C3aR/C5aR-positive microglia were higher in chronic/
inactive lesions than in the few active plaques observed.
The abundance of C3aR/C5aR-positive microglia in the
peri-plaque suggests a capacity for locally generated C3a
and C5a to recruit and activate microglia even in late
lesions.
Conclusions
This study supports the concept of progressive inflam-
mation in late stage disease, driven by complement and
contributing to cell, axon and myelin damage, microglial
activation and chemoattraction. Selective recruitment of
complement regulators to sites of activation may give
further clues to underlying pathology. The findings sup-
port the validity of measurements of serum complement
activation and of imaging complement activation as ways
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Imaging complement activation using labelled antibodies
or ligands to target activation products is a rapidly
evolving concept that might find particular relevance in
MS and other CNS diseases [34,35]. Our data show that
C1q, iC3b and TCC all present viable imaging targets in
MS. Identification of complement activation through a
combination of imaging and plasma markers might iden-
tify those patients most likely to benefit from the grow-
ing list of anti-complement therapies.Additional files
Additional file 1: Table S1. Antibodies used for immunohistochemistry.
Additional file 2: Figure S1. Control sections. Figures showing
examples of complement immunolabelling in paraffin wax sections from
white matter from cases of acute and chronic neurological inflammation
and normal control white matter immunostained with antibodies to C3b,
C1q and C1 inhibitor. Alzheimer’s disease (AD), cases A192 and A173
(plates A1-A5), shows minimal immunolabelling of complement except
within the amyloid plaque (inset A1). Herpes Simplex Virus encephalitis
(HSV), cases B5046-15 and B5125-9 (B1-5) shows more cellular and
non-cellular immunolabelling of complement. Cellular immunolabelling of
C3b (C1), C1q (C2) and C1inh (C3) is demonstrated in white matter of a case
of ischaemic stroke (case 122891-b) with immunolabelling of macrophages
and microglia within the infarcted tissue. Non-neurological control
white matter, cases C041 and C038 (D1-5) showed minimal complement
immunolabelling. Double labelling in both neurological and non-neuro-
logical control cases demonstrated colocalisation of C3b with HLA positive
microglia (D4) but not GFAP positive astrocytes (D5). E1 demonstrates
positive immunolabelling of C3b within the glomeruli of kidney sections with
glomerulonephritis. E2 (C1q) and E3 (C1inh) demonstrate C1q deposition on
the cardiac myocardial cells and C1 inh located on the sarcolemma in cardiac
myocytes in section of myocardium from patients with myocarditis due to
an adenovirus infection. Isotype anti-IgG1 (F, case MS64_B) and anti-IgG2
(not shown) were consistently immunonegative. MS tissue containing an
active plaque (G) with a small diameter blood vessel demonstrated
immunolabelling of T lymphocytes with in the blood vessel wall and
occasionally within the perivascular space; minimal positive
immunolabelling for anti -CD3 was is seen in the plaque. Scale bar is
shown in A1 and is applicable for plate A, B, C and D. Scale bars for
plates E, F and G are shown on each plate.
Additional file 3: Figure S2. Complement anaphylatoxin receptors.
Paraffin wax sections immunolabelled with anti-C3aR (A1-4) and anti-
C5aR (B1-4). Figure A1 (case MS307_20, inactive plaque) and B1 (case
MS230_S2, chronic active plaque) shows a low power image of the
plaque (P) and peri-plaque (PP) with immunolabelled C3aR (A1) and C5aR
(B1) cells. Immunopositive C3aR and C5aR labelled cells are seen
predominantly at the lesion edge; C3aR demonstrated in A2 (case
MS307_20, inactive plaque) and C5aR in B2 (case MS160_S3/1 chronic
active plaque). Both C3aR (A3, case MS312_19, chronic active plaque) and
C5aR (B3, case MS307_20, inactive plaque) (grey) were shown to co-
localise with HLA-DR +microglia (brown, arrow). No co-localisation was
shown with GFAP + astrocytes (brown); C3aR demonstrated in A4 (case
MS312_19, chronic active plaque) and C5aR in B4 (case MS307_20,
inactive plaque) (grey). Scale bars are shown for each slide.
Additional file 4: Figure S3. Complement antibody staining in MS.
Plate A demonstrates paraffin wax sections showing anti-C4d immune-
positive cells of astrocyte morphology in an active lesion (case MS179_B).
Alternative pathway component Bb is shown in plate B on immunola-
belled cells within a chronic active plaque (case MS225_S13; arrow indi-
cates an immunolabelled cell of astrocyte morphology). C shows
immunolabelling with anti-TCC demonstrating immune-positive cells with
astrocyte morphology (arrow). D shows C1q immunopositive neurones in
the cortex of case MS55_B. E1 and E2 show immunolabelling with anti-C1 inhibitor demonstrating immune-positive cells with astrocyte (E1,
arrow) and microglial-like (E1, dashed arrow) morphology as well as
immunolabelling on individual myelin sheaths (E2, arrow) (both case
MS160_S1, active plaque). F1 and F2 (F1: case MS64, inactive plaque. F2:
case MS128_B, cortex) show anti-clusterin immune-positive cells of
astrocyte morphology (F1, arrow) and neurones (F2). Case MS179 is
heterozygote for the factor H (fH) Tyr402His polymorphism. Immunolabelling
with fh_His402 (fH-H) and fH-Tyr402 (fH-T) demonstrates immune-positive
cells within the plaque (G2, fH-Tyr402, arrow) and peri-plaque (G1, fH-His402,
arrow and G3, fh-Tyr402) with fragmented myelin shown in the peri-plaque
areas. G4 demonstrated neuronal immunolabelling with fH-Tyr402 within
the cortex (case MS64_B). Plate H1-H4 show immunolabelling of C1q,
clusterin (clust) and C3b within the spinal cord (case MS55_SC). H1 shows
vast immunolabelling of C1q within the peri-plaque. H2 and H3 show
immunolabelling of cells morphologically resembling astrocytes within the
plaque. H4 demonstrated C3b immunolabelling of neurones within the
cortex. Scale bar is shown in G4 and is applicable for all plates.
Additional file 5: Figure S4. Positive cellular and myelin immunolabelling
in MS and controls. Percentage of sections with positive immunolabelling
for each antibody in both cells and myelin is shown with error bars for
multiple sclerosis (MS, 42 sections from 17 cases), non-neurological controls
(C, 14 sections from 7 cases) and neurological controls (NC, 11 sections, from
9 cases). Significant results are shown by p value examining differences
between the MS group and controls or neurological controls; differences
between the control groups were not included for reasons of clarity.
Additional file 6: Figure S5. Quantitative immunolabelling of cells
from different plaque types. Quantification of immunolabelled cells is
shown for each antibody comparing different plaque types; active (130
areas examined from 8 sections with active plaques), chronic active (180
areas examined from 9 sections with chronic active plaques) and chronic
inactive (310 areas examined from 18 sections with inactive plaques).
Groups show mean values +/_ standard error and significant results are
shown by p values examining differences between active and chronic
active groups, and chronic active and chronic inactive groups.Competing interests
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